Oppenheimer lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $350 from $375 and keeps an Outperform rating on the shares. The firm is optimistic ahead of the Q3 update as it believes Madrigal’s pioneering opportunity for Rezdiffra in MASH is underappreciated due to anticipation of ESSENCE study results for semaglutide. Oppenheimer is encouraged by important dynamics going into the Q3 update.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- 3 Best Stocks to Buy Now, 10/23/2024, According to Top Analysts
- Madrigal Pharmaceuticals completes enrollment of study of Resmetirom
- Madrigal Pharmaceuticals management to meet with JMP Securities
- Madrigal Pharmaceuticals appoints Michael Charlton as SVP, clinical development
- Madrigal announces publication of results from MAESTRO-NASH trial